جستجوی استاد راهنمای دانشگاهی

John Roger Bellمشاهده پروفایل

استادیار

• Urology
• Endourology
• Benign Prostatic Hyperplasia
• +۲ مورد دیگر

John Roger Bell, MD is an Assistant Professor of Urology and Endourology Fellowship Program Director at the University of Kentucky. He specializes in the Endourology Division within the Department of Urology, focusing on advanced minimally invasive surgical techniques for kidney and urinary tract conditions. Dr. Bell completed his medical education at Tulane University in New Orleans, followed by residency training at Ochsner Clinic Foundation & Louisiana State University School of Medicine. His specialized fellowship was completed at the University of Wisconsin, Madison School of Medicine & Public Health Department of Urology. He is board-certified by the American Board of Urology. His research primarily centers on urological conditions including benign prostatic hyperplasia and urolithiasis (kidney stones), with emphasis on surgical techniques, patient outcomes, and quality of life considerations. His publication record shows consistent scholarly contribution to the field through editorial comments that provide expert perspective on contemporary urological practices and research. Dr. Bell's recent publications demonstrate his ongoing engagement with the latest developments in endourology, particularly in diagnostic imaging techniques and minimally invasive procedures. His work reflects both clinical expertise and academic leadership in the field. As Endourology Fellowship Program Director, Dr. Bell plays a critical role in training the next generation of specialized urologists, ensuring the advancement of endoscopic surgical techniques and standards of care in the field.

• Pediatric Nephrology
• Nephrotic Syndrome
• Glomerular Diseases
• +۶ مورد دیگر

Kimberly J. Reidy, MD serves as Chief of the Division of Pediatric Nephrology and Associate Professor of Pediatrics at Albert Einstein College of Medicine, practicing at Children's Hospital at Montefiore (CHAM) in the Bronx, New York. Board-certified in pediatrics and pediatric nephrology, she maintains clinical operations across multiple Montefiore network locations including The Children's Hospital at Montefiore, Montefiore Gottscho Children's Dialysis Center, and satellite campuses in Claryville, Hartsdale, and the Bronx. Education: Bachelor of Arts in Chemistry, Princeton University (1997) Doctor of Medicine, Albert Einstein College of Medicine (2002) Pediatric Residency, Children's Hospital of New York Presbyterian (2002-2005) Pediatric Nephrology Fellowship, Children's Hospital at Montefiore (2005-2008) Research Focus: Dr. Reidy's work spans clinical, translational, and bench domains within pediatric kidney disorders. Her clinical research leads NIH-funded consortia (NEPTUNE, CureGN) studying nephrotic syndrome, while translational efforts investigate APOL1 risk variants in preeclampsia outcomes. Bench research examines developmental gene mechanisms in post-injury kidney fibrosis, with consistent peer-reviewed publication across nephrology journals. Professional Recognition: Castle Connolly Top Doctors: New York Metro Area (2016-2021) Leo M. Davidoff Society for teaching excellence (2021) Leadership: Active in the American Society of Pediatric Nephrology and Neonatal Kidney Collaborative, she serves on the American Academy of Pediatrics Executive Committee for Nephrology. As an ad hoc reviewer for Pediatric Nephrology , Kidney International , and Journal of the American Society of Nephrology , she contributes to scholarly standards while mentoring through Einstein's medical education programs.

• Clinical Informatics
• Artificial Intelligence in Healthcare
• Machine Learning Applications
• +۵ مورد دیگر

Dr. Thomas Durant is an Associate Professor of Laboratory Medicine at Yale School of Medicine with a secondary appointment in Biomedical Informatics & Data Science. He serves as Medical Director of Chemical Pathology and Laboratory Informatics at Yale-New Haven Hospital and Associate Director for the ACGME Chemical Pathology Fellowship. His dual expertise bridges clinical laboratory practice with cutting-edge informatics research. Dr. Durant's educational background includes: MD from University of Connecticut, School of Medicine (2015) MA in Physical Therapy from Quinnipiac University BA in Health Sciences from Quinnipiac University (2008) Winchester Clinical Microbiology Fellowship at Yale-New Haven Hospital (2019) Residency and Chief Residency at Yale-New Haven Hospital (2018) Board certified in Clinical Pathology (2018), Medical Microbiology (2019), and Clinical Informatics (2022), Dr. Durant's research focuses on practical applications of data science in laboratory medicine. His work centers on clinical informatics, quality care initiatives, and artificial intelligence applications including machine learning for automated image classification, quantum computing in healthcare, and laboratory data analytics. He investigates stream processing of interface data for sample identification and develops innovative data management technologies to improve laboratory operations and patient care. Analysis of Dr. Durant's publication record reveals a strong progression from traditional laboratory medicine into advanced computational methods. His recent work demonstrates expertise in ensemble learning for detecting IV fluid contamination, quantum computing applications, AI model verification protocols, and biomarker analysis for acute kidney injury prediction. The research spans multiple disciplines including clinical chemistry, informatics, and data science, addressing critical challenges in diagnostic medicine. Dr. Durant maintains extensive collaborations with Yale researchers including Wade Schulz (14 publications), Joe El-Khoury (10 publications), Harlan Krumholz (5 publications), and Richard Torres (4 publications). These partnerships support research on laboratory informatics, AI applications, and quality improvement initiatives that enhance diagnostic accuracy and healthcare delivery. As Medical Director of Laboratory IT Services, Dr. Durant oversees the technological infrastructure supporting laboratory operations at Yale-New Haven Hospital. His leadership in the Chemical Pathology Fellowship program trains future specialists, while his research continues to push the boundaries of how data science transforms diagnostic medicine.

Thomas J. Velenosiمشاهده پروفایل

استادیار

• Pharmacometabolomics
• Pharmacology
• Metabolomics
• +۷ مورد دیگر

Thomas J. Velenosi is an Assistant Professor in the Faculty of Pharmaceutical Sciences at the University of British Columbia. He received his PhD in pharmacology and toxicology from Western University and completed his postdoctoral fellowship at the National Cancer Institute (National Institutes of Health). His research focuses on the intersection of pharmacology and metabolomics, particularly in cancer therapy and biomarker discovery. Institution: University of British Columbia Faculty: Faculty of Pharmaceutical Sciences Academic Rank: Assistant Professor Dr. Velenosi's research interests center around pharmacometabolomics, metabolomics, lipidomics, mass spectrometry, cancer biology, stable isotope tracing, and bioinformatics. His lab applies advanced analytical techniques to study drug treatment response and toxicity during cancer therapy, with a particular focus on identifying and characterizing metabolic biomarkers. His approach combines highly translational cancer models with computational methods to improve biomarker identification and clinical validation. The Velenosi lab's research focuses on two main areas: 1) developing computational methods for improving mass spectrometry-based metabolomics, lipidomics and stable isotope tracing, and 2) applying these techniques to cutting-edge cancer models to identify and characterize metabolic biomarkers and therapeutic targets. His work aims to bridge the gap between biomarker identification and clinical validation to facilitate personalized therapy for cancer patients. His research has resulted in numerous publications in high-impact journals, with a focus on cancer metabolism, kidney function biomarkers, and metabolic reprogramming. The most recent publications (2022-2025) show a strong trend toward precision medicine applications, particularly in triple-negative breast cancer, with emphasis on polyamine metabolism and biomarker discovery for treatment response prediction. Postdoctoral Fellowship, Canadian Institutes of Health Research, 2018 Canada Graduate Scholarship - Doctoral (CGS-D) Award, Natural Sciences and Engineering Research Council of Canada, 2012 Dr. Velenosi actively supervises graduate students in the Pharmaceutical Sciences and Bioinformatics programs, training them in state-of-the-art mass spectrometry, molecular biology, tissue culture, and animal cancer models. His lab utilizes highly controlled patient-derived xenograft models to identify and characterize metabolic biomarkers of drug effectiveness. The Velenosi lab is currently accepting applications for MSc and PhD students interested in studying metabolic biomarkers of drug response in cancer. The lab maintains a collaborative environment with regular social events, as evidenced by their summer pizza outings and holiday parties, fostering a strong team dynamic focused on advancing precision medicine for cancer treatment through metabolomics research.

• Machine Learning
• Bioinformatics
• Genomics
• +۵ مورد دیگر

Lin Xu is an Assistant Professor at the Peter O’Donnell Jr. School of Public Health, UT Southwestern Medical Center, with a joint affiliation at the Harold C. Simmons Cancer Center. Their research focuses on developing bioinformatics algorithms and deep learning models to identify disease genes and therapeutic targets, particularly in single-cell and spatial multi-omics studies. Key research areas include: Machine learning for high-dimensional genomics/transcriptomics data Algorithm development for next-generation sequencing Biomarker discovery for cancer and non-cancer diseases Integrated data management systems Since 2019, their lab has published in top-tier journals such as Nature , Science , and Cancer Cell , covering topics like disease gene identification, therapeutic targeting, and computational biology. They have secured grants from the National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), and multiple foundations including the Hyundai Foundation and Children’s Cancer Fund. Notable projects include: Development of DIGREM for multi-drug combination detection Bayesian modeling of cancer disease genes Studies on tumor microenvironment and neoantigenicity CRISPR-based therapeutic interventions Single-cell RNA sequencing applications

• Nephrology
• Renal Medicine
• Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• +۵ مورد دیگر

Professor Albert CM Ong is Professor of Renal Medicine at the University of Sheffield's School of Medicine and Population Health, where he directs specialist services for autosomal dominant polycystic kidney disease (ADPKD) and other genetic kidney diseases at the Sheffield Kidney Institute. A globally recognized expert in ADPKD research, he serves as Co-Director of the MRC-NIHR UK Renal Ciliopathies National Network (CILIAREN) and previously contributed to the European Renal Association Council. Ong studied medicine at the University of Oxford and trained as a clinician-scientist at University College London and Oxford. His research has focused on the molecular basis of cyst formation, the genetic basis for disease variability, and drug discovery in ADPKD. The Ong lab investigates cyst initiation through studies of PKD1, PKD2, and related proteins within the polycystin network, while also examining non-coding RNAs and RNA metabolism in cyst expansion. His publication portfolio demonstrates consistent advancement in understanding ADPKD mechanisms and clinical management. Recent work emphasizes AI applications for kidney volume measurement, novel therapeutic targets including glucosylceramide synthase inhibitors, and international consensus on kidney disease management. His research bridges basic molecular mechanisms with clinical translation, employing human cellular models, model organisms, computational modeling, and analysis of deeply phenotyped clinical cohorts. Recipient of the ISN Lillian Jean Kaplan International Prize for contributions to ADPKD research Held senior research fellowships from Kidney Research UK and the Wellcome Trust Extensive involvement in international clinical guideline development Professor Ong continues to provide strategic leadership in the kidney field through his roles in major research networks and clinical consortia. His work has established the Sheffield Kidney Institute as a leading center for ADPKD research and specialized clinical care, with particular expertise in complex genetic kidney disorders and the development of novel therapeutic approaches.

• Clinical Trials
• Biostatistics
• Medical Statistics
• +۴ مورد دیگر

Hakim-Moulay Dehbi is a Principal Research Fellow and Head of Statistics at the Comprehensive Clinical Trials Unit (CTU) at University College London (UCL). He serves as co-director of the online MSc Statistics for Clinical Trials program and specializes in the design and analysis of early phase clinical trials. His educational background includes a PhD in Biostatistics and MRes in Biomedical Research from Imperial College London, as well as an MSc in Medical Statistics from University College London. He was recognized by the Higher Education Authority as a Fellow in 2019. Dr. Dehbi's research spans multiple medical domains with a focus on clinical trial methodology. His work encompasses cardiovascular medicine, oncology, epidemiology, and health services research. He has contributed significantly to the design and analysis of trials in areas such as stroke management, anticoagulation therapy, AI applications in cardiology, neonatal lung disease, soft tissue sarcoma treatment, and Long COVID research. His publication record demonstrates expertise in statistical methodology for clinical trials, particularly in dose-finding studies, sample size calculation, and trial design optimization. His recent work shows increasing focus on AI applications in medical diagnostics and treatment optimization across multiple disease areas. Dr. Dehbi has received recognition for his contributions to clinical research methodology, with his work being widely cited and implemented in various clinical settings. His research has been picked up by numerous news outlets and referenced in policy documents, indicating its real-world impact. As an educator, he supervises PhD students and co-directs the MSc Statistics for Clinical Trials program, contributing to the development of the next generation of clinical trial statisticians. His collaborative network spans multiple institutions and disciplines, reflecting the interdisciplinary nature of modern clinical trials research.

• Biomaterials
• Tissue Engineering
• Cancer Mechanobiology
• +۵ مورد دیگر

Dr. Chantal Kopecky is a Lecturer at the University of New South Wales (UNSW) Sydney, affiliated with the School of Chemistry and working in the Kilian Lab within the field of Biomaterials and Tissue Engineering. She earned her PhD in Immunology from the Medical University of Vienna, Austria in 2015, specializing in cardiovascular and lipoprotein biology in chronic kidney disease, followed by an MSc in Nutrition Science from the University of Vienna in 2009. Her research spans multiple disciplines at the intersection of biomaterials, cancer biology, and metabolic disease. Dr. Kopecky's work focuses on cancer mechanobiology, developing 3D tumor microenvironments, and investigating metabolic complications in diabetes and cardiovascular disease. She has extensively utilized advanced techniques like 3D lightsheet fluorescence microscopy to visualize pathologic processes and immune cell involvement in diseases such as atherosclerosis. Her current research in the Kilian Lab centers on biomaterials approaches to cancer therapy, particularly in pancreatic cancer where she previously worked in the Pancreatic Cancer Translational Research Group from 2018-2020. Analysis of her recent publications reveals a strong focus on nanomedicine applications for cancer treatment, particularly using ceria-based nanoparticles for EGFR-targeted therapies. Her work bridges materials science with biological applications, creating innovative hydrogel platforms to model tumor microenvironments and test novel therapeutics. She has also maintained significant research in cardiovascular disease, particularly examining the renin-angiotensin system in diabetic kidney disease. UNSW Sydney School of Medical Sciences Paper of the Month award (2019) Travel grant of the Australian Atherosclerosis Society (2018) Abstract Prize of the Austrian Diabetes Society (2017) Young Investigator Fellowship of the European Society of Atherosclerosis (2016) Clinical Science award of the Austrian Society of Transplantation, Transfusion and Genetics (2015) Hans-Krister-Stummvoll prize of the Austrian Society of Nephrology (2014) Dr. Kopecky has secured multiple research grants including as Primary Investigator for the 2020-2021 project on innovative nanomedicines for pancreatic cancer drug delivery, as Secondary Investigator for the 2019-2021 MyoRobot biomechatronics project, and as Applicant and Secondary Investigator for the 2016-2020 study on empagliflozin's effects on the renin-angiotensin system. Her laboratory work in the Kilian Lab focuses on evaluating nanomedicine therapeutics in vitro and in vivo to demonstrate metabolic reprogramming in pancreatic cancer, utilizing state-of-the-art 3D lightsheet fluorescence microscopy to characterize tumor morphology and immune cell profiles.

Rob Bakerمشاهده پروفایل

استاد

• Cardiac Surgery
• Cardiovascular Perfusion
• Thoracic Surgery
• +۳ مورد دیگر

Professor Rob Baker serves as Director of the Cardiothoracic Surgery Research, Quality and Outcomes Unit at Flinders Medical Centre, and holds academic appointment as Full Member in the College of Medicine and Public Health at Flinders University. His leadership extends to directing Perfusion Services at Flinders Medical Centre, supporting Cardiac Surgery, ECMO, Organ Retrieval, and the South Australian Liver Transplant program. He also chairs the Australian and New Zealand Collaborative Perfusion Registry and participates in national cardiac surgery database committees. Professor Baker's educational background includes a B (Med) Sci (Hons) from University of Adelaide (1986), a PhD from Flinders University (1996) with thesis titled 'Sphincter of Oddi activity - An invitro study in the Australian Brush-tailed Possum', and Certified Clinical Perfusionist (CCP) certification from the Australian Board of Cardiovascular Perfusion (1998). His research focuses on improving outcomes for cardiac surgery patients through multiple critical areas including blood management, cardiovascular perfusion techniques, clinical practice improvement, data management systems, and neurocognitive effects of cardiac surgery. Professor Baker has made significant contributions to understanding mood disorders following cardiac procedures and pharmacological interventions to optimize postoperative outcomes. His work spans both clinical practice and registry-based research with strong emphasis on quality improvement initiatives and guideline establishment. Analysis of his recent publications reveals a consistent focus on outcomes research in specialized patient populations (particularly those with renal impairment), optimization of surgical techniques, and perfusion science. His work demonstrates strong collaboration across Australia and New Zealand with emphasis on registry development and quality improvement initiatives in cardiac surgery. Professor Baker's scientific achievements have been recognized with numerous prestigious awards including the John H Gibbon, Jr Award from the American Society of Extracorporeal Technology (2017), multiple Presidential Awards from the American Society of Extracorporeal Cardiovascular Perfusion, and the Inaugural Presidential Award from the Australian and New Zealand College of Perfusion (2013). As an academic supervisor, Professor Baker has mentored numerous graduate and postgraduate students, with notable successes including Phil Tully's NHMRC Postgraduate Fellowship (2013) and Frank Dalziel Prize for Best Thesis in Psychology (2011). His supervision spans diverse areas including neuropsychology in cardiac surgery, micro RNA biomarkers, ischemic preconditioning, and advanced imaging techniques. Professor Baker leads the Cardiothoracic Surgery Research, Quality and Outcomes Unit which operates as part of the Australian and New Zealand Collaborative Perfusion Registry, contributing to national and international efforts to improve cardiac surgical outcomes through data-driven quality improvement initiatives.

• Pharmacy
• Medication Management
• Chronic Kidney Disease
• +۳ مورد دیگر

Andrew P Traynor is a Professor in the Department of Pharmaceutical Care and Health Systems at the University of Minnesota College of Pharmacy. His work focuses on medication management, chronic kidney disease, and leadership development within pharmacy education and practice. Current projects include Advancing Kidney Health through Optimal Medication Management (2024-2025) and preparing pharmacists for underserved communities in Minnesota (2024). Past research explores pharmacist integration into primary care, medication management protocols, and educational frameworks for pharmacy faculty. His work aligns with UN Sustainable Development Goals related to healthcare equity and quality education. Grant history includes Preparing Pharmacists to Enhance Care (2024, PI) and Evaluation of Risk for Loss of Pharmacy Services (2007-2009, PI).

• Transplant Surgery
• Organ Transplantation
• Pancreas Transplantation
• +۳ مورد دیگر

Raja Kandaswamy is a Professor in the Department of Surgery at the University of Minnesota Medical School, specializing in transplantation surgery with a focus on pancreas and kidney transplantation. He serves as Principal Investigator for multiple research projects and maintains an extensive publication record with over 190 research outputs. His research spans critical areas including pancreas transplantation outcomes, kidney graft survival, living donor evaluation protocols, and management of transplant rejection. He is particularly recognized for advancing desensitization techniques for highly sensitized kidney transplant candidates and developing novel organ preservation methodologies. His work also addresses donor-derived infections and long-term outcomes in living kidney donors. Analysis of his 2025 publications reveals concentrated efforts on living donor safety metrics, pancreas transplantation in bariatric surgery patients, and innovative preservation technologies. These articles collectively refine criteria for donor acceptance, address infectious complications in transplantation, and aim to optimize graft survival through evidence-based clinical practices. Professor Kandaswamy has secured significant research funding as Principal Investigator for 13 projects, including major grants from Regeneron Pharmaceuticals for bispecific antibody studies in kidney transplantation and HHS/HRSA funding for the Scientific Registry of Transplant Recipients. His current portfolio includes the MOTR study on donor-derived cell-free DNA for rejection detection and desensitization protocols for highly sensitized patients. He maintains active collaboration with Hennepin Healthcare Research Institute and participates in multi-institutional networks focused on transplant registry data and clinical trial implementation.

Alexey Larionovمشاهده پروفایل

مدرس

• Bioinformatics
• Genomics
• Transcriptomics
• +۶ مورد دیگر

Dr. Alexey Larionov is a Lecturer in Bioinformatics at Cranfield University's Centre for Soil, Agrifood and Biosciences. With over 15 years of experience in applied bioinformatics, he specializes in analyzing various sequencing data types including genomics, transcriptomics, and metagenomics. Previously educated as a medical doctor in Russia (1992), he completed a PhD studying mechanisms and markers of endocrine resistance in breast cancer (1997) before transitioning to bioinformatics after earning an MSc in Applied Bioinformatics from Cranfield University (2012). His research interests span bioinformatics, genomics, transcriptomics, metagenomics, breast cancer research, endocrine resistance mechanisms, and cancer predisposition. Dr. Larionov has developed expertise in NGS data analysis, particularly focusing on heritable predisposition to cancer. His recent work has expanded into soil science applications, examining the soil microbial methylome and epigenetic memory in driving soil abiotic legacy effects. His publication trends show a progression from breast cancer research toward broader applications of bioinformatics in environmental science, with recent papers exploring soil ecosystems while maintaining his expertise in cancer genomics. His work demonstrates strong interdisciplinary connections between medical bioinformatics and environmental applications. Fellow of The Higher Education Academy (UK) Dr. Larionov supervises PhD students including Kavitha Vijeandran and John Pearce. He is a co-investigator on significant research grants including NERC's Restoring Resilient Ecosystems (NE/V006444/1) and BBSRC's Developing a resilient and regenerative tea production system (BB/Y003241/1). At Cranfield University, he teaches Python, epigenetics, proteomics, and metagenomics analysis in the Applied Bioinformatics MSc program, bridging computational methods with biological applications across multiple domains.

Seval TÜRKمشاهده پروفایل

استادیار

• Histology and Embryology
• Immunohistochemistry
• Lectin Histochemistry
• +۲ مورد دیگر

Seval TÜRK serves as an Assistant Professor in the Department of Basic Sciences at the Faculty of Dentistry, Antalya Science University since 2020. Her research integrates histological, embryological, and tissue engineering approaches with expertise in lectin histochemistry and stem cell applications. Educational background: Bachelor's in Biology, Süleyman Demirel University Faculty of Science and Literature (2008) Master's Degree, Süleyman Demirel University (2008-2010) Ph.D., Süleyman Demirel University (2011-2015) Second Doctorate in Stem Cell and Tissue Engineering, İstinye University (2022-present, thesis stage) Dr. TÜRK's research focuses on structural tissue analysis using advanced histochemical techniques, with significant contributions to gastrointestinal histology, salivary gland pathology, and reproductive tissue dynamics. Her work examines glycoconjugate distributions, endoplasmic reticulum stress mechanisms, and stem cell applications across diverse animal models. Current investigations explore natural compounds' therapeutic potential against diabetic complications and environmental stressors' impacts on organ systems. Analysis of her 2022-2025 publications reveals consistent methodological rigor in lectin histochemistry and immunohistochemistry, with increasing emphasis on stem cell integration. Key thematic clusters include: 1) Chemical compound effects (cinnamic acid, acetyl L-carnitine) on tissue pathology, 2) Electromagnetic field and toxin impacts on cellular structures, and 3) Developmental biology of mammary glands and reproductive tissues. Scientific recognition: No specific awards documented in source materials Dr. TÜRK actively contributes to departmental quality assurance processes and institutional committees. Her extensive publication record indicates successful research project leadership and likely graduate student mentorship, though specific advisee details remain unreported. Current activities include dual institutional engagement between Antalya Science University and İstinye University's stem cell research programs. Her laboratory work centers on histochemical analysis of animal tissue models, particularly rodents and avian species, with recent expansion into stem cell applications through her ongoing doctoral research.

• Ecotoxicology
• Molecular Biology
• Biochemistry
• +۳ مورد دیگر

Dr. Tvrtko Smital is an Assistant Professor and Head of the Laboratory for Molecular Ecotoxicology at the Ruđer Bošković Institute (Division for Marine and Environmental Research). He holds a PhD in Biology-Ecotoxicology from the University of Zagreb and teaches courses including Ecotoxicology at the University of Osijek and Biological Effects of Pollutants at the University of Zagreb. His research focuses on molecular ecotoxicology, particularly the role of transport proteins (e.g., ABC transporters, OATPs) in detoxification mechanisms of aquatic organisms. Key interests include: Multixenobiotic resistance in fish and invertebrates Interactions of environmental contaminants (pharmaceuticals, microplastics, cyanotoxins) with cellular transporters Biomarker development for environmental risk assessment His recent publications (2018–2024) predominantly explore zebrafish models to investigate detoxification pathways, pollutant biodegradation, and transporter inhibition mechanisms. Trends include advanced molecular characterization of solute carriers (SLCs), ecotoxicological profiling of emerging contaminants, and novel methods for toxicity screening. He leads significant projects, including an EU-funded initiative on Ecotoxicological Characterization of Marine Environment Samples (2017–2021) and a Croatian Science Foundation project on SLC/MATE Transporters in Zebrafish (2020–2023). His laboratory utilizes cell lines (PLHC-1), molecular tools, and in vivo models to study contaminant impacts.

Lindsay E. Y. Kuoمشاهده پروفایل

دانشیار

• Endocrine Surgery
• Thyroid Cancer
• Health Disparities
• +۴ مورد دیگر

Lindsay E. Y. Kuo, MD, MBA, FACS is an Associate Professor of Surgery at the Lewis Katz School of Medicine at Temple University. She is a high-volume endocrine surgeon specializing in thyroid, parathyroid, and adrenal gland surgery with expertise in minimally invasive techniques including retroperitoneoscopic adrenalectomy, one of only two surgeons in the Philadelphia region performing this specialized procedure. Her clinical interests span the full spectrum of endocrine disorders including adrenal cancer, adrenal masses, aldosteronomas/Conn Syndrome, Cushing Syndrome, pheochromocytomas, hyperparathyroidism, parathyroid cancer, Graves' disease, hyperthyroidism, thyroid cancer, thyroid nodules, neck masses, and multiple endocrine neoplasia. Her research focuses on health disparities and access to care, as well as surgical decision-making and the extent of surgery, particularly for thyroid cancer. Dr. Kuo's publication record demonstrates expertise in surgical outcomes research, with particular emphasis on endocrine surgery, minimally invasive techniques, healthcare disparities, and surgical education. Her work spans surgical decision-making, quality improvement, and healthcare access issues, with a strong focus on evidence-based approaches to endocrine surgical care. Professional Recognition Top Doctors, Surgery, Philadelphia magazine (2023-2025) Gordon P. Buzby Surgical Leadership Award, Department of Surgery, University of Pennsylvania (2015) Administrative Chief Resident, Department of Surgery, University of Pennsylvania (2013-2015) Resident Leadership Scholarship, Residents and Associates Section, American College of Surgeons (2015) Dr. Kuo maintains active professional memberships in the American Thyroid Association, Association of Women Surgeons, American Association of Endocrine Surgeons, Society of Asian Academic Surgeons, American College of Surgeons, Association of Academic Surgeons, and Philadelphia Academy of Surgery. Her treatment philosophy centers on patient-centered care, advocating for each patient like a family member while ensuring a smooth experience from diagnosis through surgery and postoperative care.